Tempus ECG-Low EF vs EchoNext
AI Verdict
Choose Tempus ECG-Low EF if…
Choose Tempus ECG-Low EF if your primary goal is to screen patients aged 40 or older who are at risk of heart failure for signs of low left ventricular ejection fraction (LVEF ≤40%) using routine 12-lead ECG recordings. This tool provides a binary output (Low LVEF Detected / Not Detected) to help clinicians identify individuals who may require further evaluation, such as an echocardiogram.
View Tempus ECG-Low EF →Choose EchoNext if…
Choose EchoNext if you need a comprehensive AI-powered screening tool to detect a broader range of hidden structural heart diseases, including heart failure, valve disease, and pulmonary hypertension, from standard ECGs. This tool is ideal for identifying patients who should be referred for a full echocardiogram to diagnose conditions that might otherwise go undiagnosed until symptoms appear.
View EchoNext →When choosing between Tempus ECG-Low EF and EchoNext, physicians should consider their primary diagnostic focus and operational needs. Tempus ECG-Low EF excels in a very specific area: identifying signs associated with low left ventricular ejection fraction (LVEF ≤40%) in at-risk patients 40 years or older. Its output is a binary ‘Low LVEF Detected / Not Detected,’ making it a targeted screening tool for potential heart failure. This tool is best suited for practices or departments where early identification of reduced LVEF is a key concern, such as internal medicine or emergency medicine, to prompt further cardiac evaluation.
EchoNext, on the other hand, offers a broader scope, analyzing standard ECGs to detect a range of hidden structural heart diseases, including heart failure, valve disease, and pulmonary hypertension. The key practical difference lies in this breadth of detection versus the specificity of Tempus. EchoNext is integrated through the OpenEvidence platform and may be more suitable for practices seeking a comprehensive AI-powered ECG analysis for various cardiac conditions. Physicians in family medicine or general cardiology who need a wider net for structural heart disease screening might find EchoNext more aligned with their diagnostic workflow.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Tempus ECG-Low EF | EchoNext |
|---|---|---|
| Pricing | Contact vendor | Starts at $600/month |
| Deployment | Software, integrated into healthcare facility workflows | Available through the OpenEvidence clinical decision support platform. |
| BAA Available | Yes AI-estimated | Yes AI-estimated |
| FDA Status | Yes AI-estimated | Yes AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
EchoNextEchoNext is available through the OpenEvidence clinical decision support platform, which is used by a large number of U.S. physicians, suggesting a more seamless integration into existing workflows. Tempus ECG-Low EF, while integrated into healthcare facility workflows, does not have a dedicated user interface and relies on standard communication protocols for input and output, which might imply a less direct user experience.
Clinical Value
EchoNextEchoNext detects a broader range of structural heart diseases, including heart failure, valve disease, and pulmonary hypertension, with six FDA clearances. Tempus ECG-Low EF focuses specifically on detecting signs associated with low left ventricular ejection fraction. Additionally, EchoNext has demonstrated higher accuracy than cardiologists, even those with AI assistance, in identifying structural heart problems.
Pricing & Value
EchoNextEchoNext offers transparent tiered pricing starting at $600/month, including options for smaller and larger institutions, with an annual discount and add-ons. Tempus ECG-Low EF requires contacting the vendor for pricing, which offers less transparency upfront. While both offer significant clinical value, EchoNext's clear pricing structure provides a better understanding of the investment required.
Enterprise Readiness
Tempus ECG-Low EFTempus AI is a larger, more established company with a broader portfolio of AI-powered precision medicine services and a history of strategic acquisitions and partnerships, including a joint venture with SoftBank. Pathway Labs, while having secured seed funding and partnerships, appears to be a newer company with a more focused product offering at this stage.
Innovation
EchoNextEchoNext's ability to detect a wider array of hidden structural heart diseases from a standard ECG, including conditions not previously detectable by ECG, represents a significant innovative leap in early detection. The reported case of an AI-triggered heart transplant further highlights its innovative impact. While Tempus ECG-Low EF is innovative in its specific detection of low LVEF, EchoNext's broader diagnostic capability from a single ECG demonstrates a wider innovative scope.
Support & Docs
TieBoth tools are FDA-cleared and are intended for integration into healthcare facility workflows, implying a level of documentation and support for clinical use. However, specific details regarding the depth and accessibility of their support and documentation (e.g., user manuals, technical support channels, training programs) are not provided in the given information or readily available through general web searches for either product. Therefore, it is not possible to definitively pick a winner in this dimension.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Tempus ECG-Low EF | EchoNext |
|---|---|---|
| Tool Name | Tempus ECG-Low EF | EchoNext |
| Company | Tempus AI | Pathway Labs |
| Description | FDA-cleared AI software that analyzes 12-lead ECG recordings to detect signs associated with low left ventricular ejection fraction (LVEF u226440%) in patients 40 years or older at risk of heart failure. It provides a binary output to aid clinicians in further evaluation. | FDA-cleared AI tool that analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension. |
| Key Detections | Signs of low Left Ventricular Ejection Fraction (LVEF u226440%) | Hidden structural heart disease, heart failure, valve disease, pulmonary hypertension |
| Target Patient Population/Age | Patients 40+ years at risk of heart failure | Not specified |
Videos
Demos, reviews, and walkthroughs featuring Tempus ECG-Low EF and EchoNext.